Open access

Research Article

9 January 2020

Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison

Authors: Beth L Nordstrom [email protected], Mustafa Oguz, Bong Chul Chu, Mario Ouwens, Henrik-Tobias Arkenau, and Alyssa B KleinAuthor Info & Affiliations

Publication: Journal of Comparative Effectiveness Research

Volume 9, Number 3

https://doi.org/10.2217/cer-2019-0163

PDF OtherFormats

Abstract

Aim: To compare the overall survival of patients with metastatic urothelial carcinoma (mUC) who failed platinum-based chemotherapy and received durvalumab or chemotherapy. Patients & methods: In an indirect comparison of patients with mUC who failed platinum-based chemotherapy, those who received durvalumab in a single-arm study were matched to patients from the Flatiron oncology electronic medical record database who received chemotherapy (n = 158 for each cohort). Matching was based on propensity scores. Kaplan–Meier methods and Cox regression models were utilized. Results: Median overall survival was 11.2 months (95% CI: 7.2–16.9) for durvalumab versus 8.2 months (95% CI: 6.7–9.8) for chemotherapy (hazard ratio: 0.63; 95% CI: 0.48–0.84). Conclusion: As a second-line therapy for mUC, durvalumab was associated with longer overall survival than chemotherapy.

Formats available

You can view the full content in the following formats:

View PDF View Full Text

References

Papers of special note have been highlighted as: • of interest •• of considerable interest

1.

Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 78(7), 1505–1513 (1996).

2.

Powles T. Immunotherapy: the development of immunotherapy in urothelial bladder cancer. Nat. Rev. Clin. Oncol. 12(4), 193–194 (2015).

3.

American Cancer Society. Key Statistics for Bladder Cancer (2016). https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html

4.

Bellmunt J, Albiol S, Suarez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit. Rev. Oncol. Hematol. 69(3), 211–222 (2009).

5.

Calabro F, Sternberg CN. State-of-the-art management of metastatic disease at initial presentation or recurrence. World J. Urol. 24(5), 543–556 (2006).

6.

Rosenberg JE, Von Der Maase H, Seigne JD et al. A Phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 103(10), 2035–2041 (2005).

7.

Sengelov L, Kamby C, Geertsen P, Andersen LJ, Von Der Maase H. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother. Pharmacol. 46(5), 357–364 (2000).

8.

Bellmunt J, Fougeray R, Rosenberg JE et al. Long-term survival results of a randomized Phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann. Oncol. 24(6), 1466–1472 (2013).

•• A Phase III study demonstrating the long-term survival of second-line chemotherapy for advanced urothelial carcinoma. The results of this study helped to establish an overall survival benchmark for second-line chemotherapy in this indication.

9.

Jiang DM, Sridhar SS. Prime time for immunotherapy in advanced urothelial cancer. Asia Pac. J. Clin. Oncol. 14(Suppl. 5), 24–32 (2018).

10.

Flaig TW, Pe Spiess PE, Agarwal N et al. NCCN Guidelines Insights: Bladder Cancer, Version 5 2018. J. Natl Compr. Canc. Netw. 16(9), 1041–1053 (2018).

11.

Powles T, O’donnell PH, Massard C et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a Phase I/II open-label study. JAMA Oncol. 3(9), e172411–e172411 (2017).

•• Phase I/II study that established the clinical benefit of durvalumab as a second-line therapy for locally advanced or metastatic urothelial carcinoma. Results of this study supported regulatory approval of durvalumab in this indication.

12.

Imfinzi (Durvalumab). [prescribing information] AstraZeneca Pharmaceuticals LP, DE, USA (2018).

13.

Flatiron Health. Flatiron Health Database (2019). https://flatiron.com/real-world-evidence/

14.

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46(3), 399–424 (2011).

15.

Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 10(2), 150–161 (2011).

16.

Stuart EA. Matching methods for causal inference: a review and a look forward. Stat. Sci. 25(1), 1–21 (2010).

17.

Ellis LM, Bernstein DS, Voest EE et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol. 32(12), 1277–1280 (2014).

•• A summary of recommendations by four disease-specific working groups, convened by the ASCO Cancer Research Committee, to define clinically meaningful outcomes for clinical trials of solid tumors.

18.

Hoos A, Britten C. The immuno-oncology framework: enabling a new era of cancer therapy. Oncoimmunology 1(3), 334–339 (2012).

19.

Hoos A, Eggermont AMM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388–1397 (2010).

• A review addressing the potential for a delayed separation in Kaplan–Meier survival curves with immunotherapy agents, and how this needs to be taken into account when evaluating these agents in clinical trials (including different statistical approaches).

20.

Powles T, Galsky MD, Castellano D et al. A Phase III study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE. J. Clin. Oncol. 34(Suppl. 15), Abst TPS4574 (2016).

• Describes an ongoing Phase III study to evaluate the efficacy and safety of durvalumab, alone or in combination with an anti-CTLA-4 agent, in patients with previously untreated, metastatic urothelial carcinoma.

21.

Tripathi A, Plimack ER. Immunotherapy for urothelial carcinoma: current evidence and future directions. Curr. Urol. Rep. 19(12), 109 (2018).

22.

Stenehjem DD, Tran D, Nkrumah MA, Gupta S. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco. Targets Ther. 11, 5973–5989 (2018).

23.

Weng YM, Peng M, Hu MX, Yao Y, Song QB. Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. Onco. Targets Ther. 11, 7529–7542 (2018).

• Describes the findings of a meta-analysis to evaluate the clinical and molecular characteristics associated with overall survival outcomes with PD-1/PD-L1 inhibitors in solid tumors, including urothelial carcinoma.

|